Pfizer Total Current Assets 2010-2024 | PFE

Pfizer total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
  • Pfizer total current assets for the quarter ending September 30, 2024 were $43.223B, a 41.6% decline year-over-year.
  • Pfizer total current assets for 2023 were $43.333B, a 15.46% decline from 2022.
  • Pfizer total current assets for 2022 were $51.259B, a 14.13% decline from 2021.
  • Pfizer total current assets for 2021 were $59.693B, a 70.23% increase from 2020.
Pfizer Annual Total Current Assets
(Millions of US $)
2023 $43,333
2022 $51,259
2021 $59,693
2020 $35,067
2019 $32,803
2018 $49,926
2017 $41,141
2016 $38,949
2015 $43,804
2014 $55,595
2013 $56,244
2012 $64,831
2011 $60,817
2010 $61,013
2009 $61,670
Pfizer Quarterly Total Current Assets
(Millions of US $)
2024-09-30 $43,223
2024-06-30 $37,825
2024-03-31 $42,415
2023-12-31 $43,333
2023-09-30 $74,012
2023-06-30 $73,347
2023-03-31 $50,078
2022-12-31 $51,259
2022-09-30 $70,403
2022-06-30 $67,466
2022-03-31 $54,420
2021-12-31 $59,693
2021-09-30 $57,900
2021-06-30 $48,814
2021-03-31 $39,533
2020-12-31 $35,067
2020-09-30 $47,739
2020-06-30 $46,424
2020-03-31 $34,738
2019-12-31 $32,803
2019-09-30 $33,459
2019-06-30 $47,073
2019-03-31 $45,290
2018-12-31 $49,926
2018-09-30 $41,583
2018-06-30 $37,303
2018-03-31 $34,835
2017-12-31 $41,141
2017-09-30 $40,291
2017-06-30 $36,385
2017-03-31 $35,878
2016-12-31 $38,949
2016-09-30 $38,501
2016-06-30 $43,845
2016-03-31 $41,298
2015-12-31 $43,804
2015-09-30 $45,001
2015-06-30 $51,715
2015-03-31 $49,443
2014-12-31 $55,595
2014-09-30 $56,987
2014-06-30 $58,287
2014-03-31 $57,793
2013-12-31 $56,244
2013-09-30 $59,500
2013-06-30 $61,435
2013-03-31 $64,763
2012-12-31 $64,831
2012-09-30 $57,127
2012-06-30 $58,765
2012-03-31 $54,863
2011-12-31 $60,817
2011-09-30 $62,732
2011-06-30 $60,484
2011-03-31 $58,244
2010-12-31 $61,013
2010-09-30 $54,089
2010-06-30 $51,101
2010-03-31 $49,916
2009-12-31 $61,670
2009-09-30 $73,784
2009-06-30 $71,550
2009-03-31 $54,253
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $142.241B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94